MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a

Journal of Neuroimmunology

Volumn 278, Issue , 2015, Pages 185-189

  Aung, Latt Latt ^a   Mouradian, M Maral ^a   Dhib Jalbut, Suhayl ^a   Balashov, Konstantin E ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

B lymphocytes; MicroRNA; MiR 320a; MMP 9; Multiple sclerosis

Indexed keywords

GELATINASE B; MICRORNA; MICRORNA 132; MICRORNA 212; MICRORNA 320A; MICRORNA 491; UNCLASSIFIED DRUG; INTERLEUKIN 6; MESSENGER RNA; MIRN320 MICRORNA, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION; GENE LOCATION; HUMAN; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; RELAPSE; UPREGULATION; ADOLESCENT; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; B-LYMPHOCYTES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MICRORNAS; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TRANSFECTION; YOUNG ADULT;

EID: 84920913913     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.11.004     Document Type: Article

References (41)

1. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
2. Asahi M., Wang X., Mori T., Sumii T., Jung J.C., Moskowitz M.A., et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci. 2001, 21:7724-7732.
3. Balashov K.E., Aung L.L., Vaknin-Dembinsky A., Dhib-Jalbut S., Weiner H.L. Interferon-beta inhibits toll-like receptor 9 processing in multiple sclerosis. Ann. Neurol. 2010, 68:899-906.
4. Baranzini S.E., Jeong M.C., Butunoi C., Murray R.S., Bernard C.C., Oksenberg J.R. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J. Immunol. 1999, 163:5133-5144.
5. Bar-Or A., Nuttall R.K., Duddy M., Alter A., Kim H.J., Ifergan I., et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
6. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63:395-400.
7. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 2012, 1825:29-36.
8. Bronisz A., Godlewski J., Wallace J.A., Merchant A.S., Nowicki M.O., Mathsyaraja H., et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat. Cell Biol. 2012, 14:159-167.
9. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 1995, 201:223-226.
10. Correale J., Fiol M., Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006, 67:652-659.
11. Cross A.H., Waubant E. MS and the B cell controversy. Biochim. Biophys. Acta 2011, 1812:231-238.
12. Davidson-Moncada J., Papavasiliou F.N., Tam W. MicroRNAs of the immune system: roles in inflammation and cancer. Ann. N. Y. Acad. Sci. 2010, 1183:183-194.
13. Fainardi E., Castellazzi M., Bellini T., Manfrinato M.C., Baldi E., Casetta I., et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult. Scler. 2006, 12:294-301.
14. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
15. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000, 343:898-904.
16. Kappos L., Bates D., Edan G., Eraksoy M., Garcia-Merino A., Grigoriadis N., et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011, 10:745-758.
17. Kappos L., Li D., Calabresi P.A., O'Connor P., Bar-Or A., Barkhof F., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378:1779-1787.
18. Kuenz B., Lutterotti A., Ehling R., Gneiss C., Haemmerle M., Rainer C., et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008, 3:e2559.
19. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983, 33:1444-1452.
20. Kurzepa J., Bartosik-Psujek H., Suchozebrska-Jesionek D., Rejdak K., Stryjecka-Zimmer M., Stelmasiak Z. Role of matrix metalloproteinases in the pathogenesis of multiple sclerosis. Neurol. Neurochir. Pol. 2005, 39:63-67.
21. Lee M.A., Palace J., Stabler G., Ford J., Gearing A., Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999, 122(Pt 2):191-197.
22. Leppert D., Lindberg R.L., Kappos L., Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Brain Res. Rev. 2001, 36:249-257.
23. Lindberg R.L., Hoffmann F., Mehling M., Kuhle J., Kappos L. Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. Eur. J. Immunol. 2010, 40:888-898.
24. Lovato L., Willis S.N., Rodig S.J., Caron T., Almendinger S.E., Howell O.W., et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 2011, 134:534-541.
25. Lu L.F., Liston A. MicroRNA in the immune system, microRNA as an immune system. Immunology 2009, 127:291-298.
26. Maurano M.T., Humbert R., Rynes E., Thurman R.E., Haugen E., Wang H., et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012, 337:1190-1195.
27. Naismith R.T., Piccio L., Lyons J.A., Lauber J., Tutlam N.T., Parks B.J., et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010, 74:1860-1867.
28. Obermeier B., Lovato L., Mentele R., Bruck W., Forne I., Imhof A., et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J. Neuroimmunol. 2011, 233:245-248.
29. O'Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10:111-122.
30. Oviedo-Orta E., Bermudez-Fajardo A., Karanam S., Benbow U., Newby A.C. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008, 124:42-50.
31. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
32. Qin Y., Duquette P., Zhang Y., Talbot P., Poole R., Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 1998, 102:1045-1050.
33. Racke M.K. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 2008, 21(Suppl. 1):S9-S18.
34. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., Terol M.J., Garcia-Marco J.A., Garcia-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006, 108:3143-3151.
35. Sievers C., Meira M., Hoffmann F., Fontoura P., Kappos L., Lindberg R.L. Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. Clin. Immunol. 2012, 144:70-79.
36. Sonkoly E., Stahle M., Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin. Cancer Biol. 2008, 18:131-140.
37. Sorensen P.S., Lisby S., Grove R., Derosier F., Shackelford S., Havrdova E., et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014, 82:573-581.
38. Trocme C., Gaudin P., Berthier S., Barro C., Zaoui P., Morel F. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9. J. Biol. Chem. 1998, 273:20677-20684.
39. Ucar A., Vafaizadeh V., Jarry H., Fiedler J., Klemmt P.A., Thum T., et al. miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat. Genet. 2010, 42:1101-1108.
40. von Budingen H.C., Kuo T.C., Sirota M., van Belle C.J., Apeltsin L., Glanville J., et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J. Clin. Invest. 2012, 122:4533-4543.
41. Yan W., Zhang W., Sun L., Liu Y., You G., Wang Y., et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011, 1411:108-115.